MP26-01 PRETREATMENT NEUTROPHIL-TO-LYMPHOCYTE RATIO IS A NOVEL BIOMARKER FOR PREDICTING WORSE CLINICAL OUTCOME IN CHEMO-RESISTANT UROTHELIAL CARCINOMA PATIENTS TREATED WITH PEMBROLIZUMAB

MLA

Syunsuke Yoshimine, et al. “Mp26-01 Pretreatment Neutrophil-To-Lymphocyte Ratio Is a Novel Biomarker for Predicting Worse Clinical Outcome in Chemo-Resistant Urothelial Carcinoma Patients Treated with Pembrolizumab.” Journal of Urology, vol. 201, Apr. 2019. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........cd380ae5f4a01c49bff3df366f17edb1&authtype=sso&custid=ns315887.

APA

Syunsuke Yoshimine, Seiya Hattori, Koichiro Ogihara, Satoshi Hara, Takashi Okabe, Masafumi Oyama, Eiji Kikuchi, Suguru Shirotake, Ryuichi Mizuno, Takeshi Masuda, Masashi Niwakawa, Ryo Yamashita, Mototsugu Oya, & Kazuhiro Matsumoto. (2019). Mp26-01 Pretreatment Neutrophil-To-Lymphocyte Ratio Is a Novel Biomarker for Predicting Worse Clinical Outcome in Chemo-Resistant Urothelial Carcinoma Patients Treated with Pembrolizumab. Journal of Urology, 201.

Chicago

Syunsuke Yoshimine, Seiya Hattori, Koichiro Ogihara, Satoshi Hara, Takashi Okabe, Masafumi Oyama, Eiji Kikuchi, et al. 2019. “Mp26-01 Pretreatment Neutrophil-To-Lymphocyte Ratio Is a Novel Biomarker for Predicting Worse Clinical Outcome in Chemo-Resistant Urothelial Carcinoma Patients Treated with Pembrolizumab.” Journal of Urology 201 (April). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........cd380ae5f4a01c49bff3df366f17edb1&authtype=sso&custid=ns315887.